LFCRHealthcare · Drug Manufacturers - Specialty & GenericThe 5 Wall Street analysts covering Lifecore Biomedical, Inc. hold a median 12-month price target of $6.25 — +51.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lifecore Biomedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 June 2026 | Barrington Research | Maintains | Outperform | $6.00 → $6.50 |
| 29 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 27 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 17 Mar 2026 | Barrington Research | Upgrade | Outperform | — |
| 4 Sept 2025 | Keybanc | Initiates | Sector Weight | — |
| 21 May 2025 | William Blair | Initiates | Outperform | — |
| 3 Jan 2025 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 22 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 5 Sept 2024 | Craig-Hallum | Initiates | Buy | — |
| 28 Aug 2024 | Barrington Research | Downgrade | Market Perform | — |
| 1 Sept 2023 | Barrington Research | Maintains | Outperform | — |
| 1 Sept 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
| 2 June 2023 | Barrington Research | Maintains | Outperform | — |
| 24 May 2023 | Barrington Research | Maintains | Outperform | — |
| 21 Mar 2023 | Barrington Research | Maintains | Outperform | — |
| 20 Mar 2023 | Barrington Research | Maintains | Outperform | — |
| 20 Mar 2023 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 17 Mar 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 9 Dec 2022 | Baird | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Lifecore Biomedical, Inc. returned −46.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 65% of US stocks
Cheaper than 96% of US stocks
Cheaper than 6% of US stocks
Higher than 85% of US stocks
Higher than 33% of US stocks
Higher than 43% of US stocks
Higher than 60% of US stocks
Higher than 15% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lifecore Biomedical, Inc. has a market value of $156.3M and an enterprise value of $345.3M.
Revenue in the twelve months to 30 June 2026: $124.9M. The latest quarter grew 47.3% year on year.
Net income over the same four quarters: −$32.3M, a −25.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.97.
Free cash flow in the twelve months to 30 June 2026: $4.2M.
Trailing P/E: 56.2×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Lifecore Biomedical, Inc. employs 382 people — $327K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifecore Biomedical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lifecore Biomedical announced that it will participate at the CPHI Global Conference. The announcement was made by the company, a fully integrated injectables CDMO, on September 3, 2026.
Why it matters — CPHI Global Conference participation provides Lifecore with a platform to engage with industry peers and potential clients in the contract development and manufacturing space.
Lifecore Biomedical announced it has signed a new agreement to transfer a commercially marketed drug product to its pipeline, supporting technology transfer and commercial manufacturing for a global pharmaceutical company. The program is expected to become one of Lifecore's largest contracts and contribute to 2028 commercial revenues.
Why it matters — This new agreement positions Lifecore to gain a significant manufacturing contract and a future revenue stream that could become one of its largest programs.
Seeking Alpha published the transcript of Lifecore Biomedical's second-quarter fiscal 2026 earnings call. The item is a record of the company's earnings call discussion.
Why it matters — Lifecore watchers use the transcript to review management's commentary on the company's latest quarterly results.
Lifecore Biomedical reported financial results for the second quarter and six months ended June 30, 2026. The company reaffirmed its 2026 guidance, announced multiple new business wins that add programs to its pipeline, and highlighted ongoing cost reduction and productivity enhancements, with a conference call held at 8:00am ET.
Why it matters — LFCR watchers would look for signs that the CDMO is holding its full-year outlook while expanding its pipeline through new client wins and ongoing operational improvement.
Lifecore Biomedical announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
Why it matters — A LFCR watcher would want to know the scheduled date for the company's quarterly earnings release to anticipate the upcoming financial performance update.
The 5 Wall Street analysts covering Lifecore Biomedical, Inc. have a median 12-month price target of $6.25, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Lifecore Biomedical, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifecore Biomedical, Inc. 3 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Lifecore Biomedical, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +51.3% from the last close, and Ticker Nerd's factor model ranks Lifecore Biomedical, Inc. 3 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifecore Biomedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
Lifecore Biomedical, Inc. returned -46.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products.
The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Lifecore Biomedical to Participate at CPHI Global Conference". Lifecore Biomedical announced that it will participate at the CPHI Global Conference. The announcement was made by the company, a fully integrated injectables CDMO, on September 3, 2026.
Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products. The company provides development, aseptic fill-finish, and commercial manufacturing services for products packaged in syringes, vials, and cartridges. It also produces pharmaceutical-grade hyaluronic acid, a biomaterial used in a range of medical applications, including ophthalmic and orthopedic products. Lifecore Biomedical Inc. serves pharmaceutical and medical device customers that need regulated manufacturing expertise, formulation support, and process scale-up capabilities. Headquartered in Chaska, Minnesota, the company operates in the biopharmaceutical manufacturing and biomaterials markets, where it plays a specialized role in supporting complex injectable therapies and related healthcare products.
CEO Mr. Paul Josephs · 382 employees · United States · https://www.lifecore.com
